Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · IEX Real-Time Price · USD

7.73

-0.33 (-4.09%)

At close: Jul 2, 2024, 4:00 PM

7.74

+0.01 (0.14%)

After-hours: Jul 2, 2024, 7:54 PM EDT

Iovance Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2007
Net Income	-444.04	-395.89	-342.25	-259.58	-197.56	Upgrade
Depreciation & Amortization	33.13	21.14	13.98	8.71	8.12	Upgrade
Share-Based Compensation	62.63	84.02	69.77	40.89	24.28	Upgrade
Other Operating Activities	-13.54	-2.02	30.57	4.85	6.27	Upgrade
Operating Cash Flow	-361.82	-292.76	-227.94	-205.13	-158.89	Upgrade
Capital Expenditures	-22.29	-20.43	-37.57	-46.79	-6.92	Upgrade
Acquisitions	-212.63	0	0	0	0	Upgrade
Change in Investments	79.68	276.88	37.71	-271.06	96.94	Upgrade
Investing Cash Flow	-155.24	256.46	0.13	-317.85	90.03	Upgrade
Share Issuance / Repurchase	465.75	192.8	238.27	576.71	6.44	Upgrade
Debt Issued / Paid	0	0	1	0	0	Upgrade
Other Financing Activities	-2.8	-2.65	-	-0.28	-0.31	Upgrade
Financing Cash Flow	462.96	190.15	239.27	576.42	6.13	Upgrade
Exchange Rate Effect	-2.74	0	0	0	0	Upgrade
Net Cash Flow	-56.84	153.85	11.46	53.44	-62.73	Upgrade
Free Cash Flow	-384.11	-313.18	-265.52	-251.93	-165.81	Upgrade
Free Cash Flow Margin	-32305.30%	-	-	-	-	Upgrade
Free Cash Flow Per Share	-1.63	-1.97	-1.73	-1.82	-1.33	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).